SUMMARY Seven infants with persistent neonatal hyperinsulinism were treated in Dhahran Health Centre from 1983 to 1986. The insulin:glucose ratio (serum insulin concentration pmolIl) divided by the blood glucose concentration (mmolI1) ranged from 12 to 636, mean (SD) 177 (201). To control hypoglycaemia, diazoxide (12-24 mg/kg/day) was given in a continuous intravenous glucose infusion (12-22 mg/kg/min) on 11 separate occasions, four infants twice each and three infants once each. An increase of more than one standard deviation in the heart and respiratory rates, together with other symptoms of heart failure, was considered to be evidence of diazoxide toxicity. Cardiorespiratory failure (toxicity) occurred on eight of the 11 occasions (73%) ...
Diazoxide is a non-diuretic benzothiadiazine derivative, one of a group of substances introduced int...
Diazoxide is the first-line drug for treating hyperinsulinism and the only pharmacological agent app...
A 3-year-old boy with Down’s syndrome with no underly-ing cardiac anomalies presented with hypoglyca...
Hypoglycemia in neonates is associated with long-term neurodevelopmental effects. Hyperinsulinemic h...
Primary persistent hyperinsulinaemic hypoglycaemia of infancy is rare. Diazoxide treatment remains t...
Background: Diazoxide is the main therapeutic agent for congenital hyperinsulinism. The drug is gene...
Diazoxide is one of the FDA-approved pharmacologic treatments for hyperinsulinemic hypoglycemia, how...
Objective: To evaluate the type and frequency of adverse effects associated with diazoxide used for ...
PubMedID: 18512033Primary persistent hyperinsulinaemic hypoglycaemia is characterised by clinical sy...
Ranjit I Kylat Division of Neonatal-Perinatal Medicine and Developmental Biology, Department of Pedi...
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI), also known as congenital hyperinsulinism...
WOS: 000418709600016Hyperinsulinemic hypoglycemia (HH) is the most common reason for persistent and ...
Long-term diazoxide and somatostatin analogue have been used in the treatment of persistent hyperins...
Recalcitrant neonatal hypoglycemia poses a treatment challenge for clinicians. When a patient's hypo...
Neonatal hyperinsulinemic hypoglycemia must be suddenly and appropriately diagnosed and treated to p...
Diazoxide is a non-diuretic benzothiadiazine derivative, one of a group of substances introduced int...
Diazoxide is the first-line drug for treating hyperinsulinism and the only pharmacological agent app...
A 3-year-old boy with Down’s syndrome with no underly-ing cardiac anomalies presented with hypoglyca...
Hypoglycemia in neonates is associated with long-term neurodevelopmental effects. Hyperinsulinemic h...
Primary persistent hyperinsulinaemic hypoglycaemia of infancy is rare. Diazoxide treatment remains t...
Background: Diazoxide is the main therapeutic agent for congenital hyperinsulinism. The drug is gene...
Diazoxide is one of the FDA-approved pharmacologic treatments for hyperinsulinemic hypoglycemia, how...
Objective: To evaluate the type and frequency of adverse effects associated with diazoxide used for ...
PubMedID: 18512033Primary persistent hyperinsulinaemic hypoglycaemia is characterised by clinical sy...
Ranjit I Kylat Division of Neonatal-Perinatal Medicine and Developmental Biology, Department of Pedi...
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI), also known as congenital hyperinsulinism...
WOS: 000418709600016Hyperinsulinemic hypoglycemia (HH) is the most common reason for persistent and ...
Long-term diazoxide and somatostatin analogue have been used in the treatment of persistent hyperins...
Recalcitrant neonatal hypoglycemia poses a treatment challenge for clinicians. When a patient's hypo...
Neonatal hyperinsulinemic hypoglycemia must be suddenly and appropriately diagnosed and treated to p...
Diazoxide is a non-diuretic benzothiadiazine derivative, one of a group of substances introduced int...
Diazoxide is the first-line drug for treating hyperinsulinism and the only pharmacological agent app...
A 3-year-old boy with Down’s syndrome with no underly-ing cardiac anomalies presented with hypoglyca...